Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging Bioidentical Hormones - U.S. Senate Special Committee on Aging
87 Dr. David Wright at Emory University Medical School in Atlanta has been testing compounded progesterone for head injury. In a 3year trial of 100 such patients, 80 received high-dose progesterone over 72 hours after trauma and 20 did not. The study on young men-not women-found that those receiving compounded progesterone were 50 percent less likely to die. There was less disability at the 1-month mark than would normally be expected considering the severity of their head injuries. Marcus Baskett of Commerce, GA, was one of those patients in a head-on automobile collision just 3 weeks shy of his high school graduation. Early tests of his brain function suggested massive and disabling head injury. He spent almost 3 weeks in a coma. Then, 4 weeks later, Baskett was released with lingering physical injuries but little evidence of the severe head trauma. Three years later, a 21-year-old Baskett is back 100 percent. There are uses for compounded bioidentical hormones that none of us have ever even imagined. To consider eliminating them is to limit the researchers' imagination everywhere. [The prepared statement of Ms. Wiley follows:]
88 Testimony Of T.S. Wiley before the
- Page 39 and 40: 1. Introduction 36 Chairman Kohl, R
- Page 41 and 42: diet and fitness products. 5 For ex
- Page 43 and 44: include "natural" progesterone crea
- Page 45 and 46: 42 unique to the computer age, such
- Page 47 and 48: computer users to spam(ftuce.0ov -
- Page 49 and 50: 46 accuracy of advertising for heal
- Page 51 and 52: 48 Now, you have identified in your
- Page 53 and 54: 50 claim." Therefore, since the ter
- Page 55 and 56: 52 Such quality control problems ha
- Page 57 and 58: 54 Statement Before the U.S. <stron
- Page 59 and 60: in the U.S., whereas WHI participan
- Page 61 and 62: 58 between science and hearsay and
- Page 63 and 64: 60 How can we determine whether bio
- Page 65 and 66: 62 doctors-are not getting the obje
- Page 67 and 68: 64 27. Writing Group for the PEPI T
- Page 69 and 70: 66 Dr. MANSON. Well, I think that m
- Page 71 and 72: 68 Statement of Leonard Wartofsky,
- Page 73 and 74: 70 in the WHI. In fact, no study as
- Page 75 and 76: In summary, the Endocrine Society i
- Page 77 and 78: 74 The FDA also regulates aspects o
- Page 79 and 80: Statement of Loyd V. Allen, Jr., Ph
- Page 81 and 82: Statement of Loyd V. Allen, Jr., Ph
- Page 83 and 84: Statement of Loyd V. Allen, Jr., Ph
- Page 85 and 86: 82 Senator SMITH. Dr. Allen, as I h
- Page 87 and 88: 84 Now, when you are talking about
- Page 89: 86 The only thing the WHI proved wa
- Page 93 and 94: Confusion and Media Hype 90 Instead
- Page 95 and 96: 92 see a doctor tell a diabetic nea
- Page 97 and 98: 94 the only compelling reason to ta
- Page 99 and 100: 96 identical hormones synthesized f
- Page 101 and 102: 98 The world as we know it, from ba
- Page 103 and 104: 100 thereby experienced long period
- Page 105 and 106: 102 Bio-identical progesterone repl
- Page 107 and 108: 104 had reached optimum theoretical
- Page 109 and 110: 106 and the patient can be can reas
- Page 111 and 112: 108 Estradiol and Analytical Resear
- Page 113 and 114: 110 A controlled systematic pilot c
- Page 115 and 116: 112 of set doses. The Wiley Protoco
- Page 117 and 118: 114 I'd advocate for either Accredi
- Page 119 and 120: 116 D.C., and established a goal to
- Page 121 and 122: 118 If this legislation passes, fed
- Page 123 and 124: first and second finger on the barr
- Page 125 and 126: 122 These products that have been s
- Page 127 and 128: 124 Bcl-2, survivin and variant CD4
- Page 129 and 130: 126 These are experiments by other
- Page 131 and 132: 128 cerebro-cellular inflammation c
- Page 133 and 134: 130 Years # women *1>0.5 8 *1+ 9 *2
- Page 135 and 136: *Breast cancer 132 -57 y.o. recurre
- Page 137 and 138: 134 *Labor intense for patient and
- Page 139 and 140: 136 Senator SMITH. Thank you very m
87<br />
Dr. David Wright at Emory University Medical School in Atlanta<br />
has been testing compounded progester<strong>on</strong>e for head injury. In a 3year<br />
trial of 100 such patients, 80 received high-dose progester<strong>on</strong>e<br />
over 72 hours after trauma and 20 did not.<br />
The study <strong>on</strong> young men-not women-found that those receiving<br />
compounded progester<strong>on</strong>e were 50 percent less likely to die.<br />
There was less disability at the 1-m<strong>on</strong>th mark than would normally<br />
be expected c<strong>on</strong>sidering the severity of their head injuries.<br />
Marcus Baskett of Commerce, GA, was <strong>on</strong>e of those patients in<br />
a head-<strong>on</strong> automobile collisi<strong>on</strong> just 3 weeks shy of his high school<br />
graduati<strong>on</strong>. Early tests of his brain functi<strong>on</strong> suggested massive and<br />
disabling head injury.<br />
He spent almost 3 weeks in a coma. Then, 4 weeks later, Baskett<br />
was released with lingering physical injuries but little evidence of<br />
the severe head trauma. Three years later, a 21-year-old Baskett<br />
is back 100 percent.<br />
There are uses for compounded bioidentical horm<strong>on</strong>es that n<strong>on</strong>e<br />
of us have ever even imagined. To c<strong>on</strong>sider eliminating them is to<br />
limit the researchers' imaginati<strong>on</strong> everywhere.<br />
[The prepared statement of Ms. Wiley follows:]